Soliton announced that the U.S. Food and Drug Administration (FDA) has cleared its Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite using the power of sound. The unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause cellulite to deliver efficacious results in just one, 40- to 60-minute treatment. "We're thrilled to receive this latest clearance for our RAP technology," says Brad Hauser, president and CEO of Soliton. "Our technology will now provide physicians a new, innovative and non-invasive approach for patients seeking a non-surgical option to improve the appearance of cellulite. This latest clearance also marks the next step in the planned commercialization of our RAP technology, and we look forward to introducing this new approach to treating cellulite to physicians in the months to come."